Accellta, the stem cell company, has granted exclusive worldwide rights to Stemcell Technologies Inc. for manufacturing and distribution of medium for culturing pluripotent stem cells in suspension under feeder-free, non-adherent conditions.

The novel medium represents a breakthrough in stem cell manufacturing technologies; it was designed by Accellta to dramatically reduce the cost and duration of pluripotent stem cell production by enabling mass culturing of cells in suspension, using a bioreactor free of micro-carriers or any other adherence surfaces, which replaces the use of numerous culture dishes or micro-carriers.

Accellta's revolutionary approach for suspension culturing of pluripotent stem cells in non-adherent conditions has been experimentally validated in numerous pluripotent stem cell lines, including embryonic and induced human pluripotent stem cells.

Dr. Itzhak Angel, Accellta's chairman and CEO, said: "Enabling large-scale production and reducing the costs of stem cell products are the key technological challenges the stem cell industry is facing today, and some of the main goals of Accellta's revolutionary technologies. We are delighted to partner with Stemcell Technologies, a global leader in stem cell culture solutions, and believe this partnership will maximize the global reach of our solutions and make a significant impact on the large-scale use, applicability and affordability of stem cell-based products".

"We are excited to bring these important products to researchers and to be the exclusive commercial supplier. Given our excellent track record and market leader status in providing high quality cell culture tools for human pluripotent stem cells, the addition of these products to our portfolio is excellent," said Dr. Allen Eaves, CEO and president of Stemcell Technologies.

Accellta was established in 2012 by the Technion and AMIT (the Alfred Mann Institute at the Technion); it offers a range of revolutionary solutions for better affordability and quality of stem cell culturing and for developing specialty media and stem cell lines and services. Accellta's unique solutions are the result of over 15 years of pioneering research and development at the Stem Cell Center of the Rappaport Faculty of Medicine at the Technion- Israel Institute of Technology.

Accellta is currently focused on creating strategic partnerships with Biopharma and stem cell companies for developing large-scale and cost-effective manufacturing processes for cell products. In the future the company is aimed at expanding the use of its technologies for in vitro toxicology studies and potential therapeutic applications of stem cells.

Accellta develops, manufactures and markets a range of revolutionary solutions for better affordability and quality of stem cell culturing and for developing specialty cell culture tools, services and cell lines.

Stemcell Technologies Inc. is a leader in the development of specialty cell culture media, cell isolation products and ancillary reagents for life science research.